Mineralys Therapeutics Inc
NASDAQ:MLYS
Relative Value
There is not enough data to reliably calculate the relative value of MLYS.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
MLYS Competitors Multiples
Mineralys Therapeutics Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
M
|
Mineralys Therapeutics Inc
NASDAQ:MLYS
|
633.8m USD | 0 | -7 | -2.8 | -2.8 | |
US |
Abbvie Inc
NYSE:ABBV
|
284.7B USD | 5.2 | 47.8 | 13.4 | 20.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
164.1B USD | 5.6 | 43.6 | 18.4 | 30.4 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.6B USD | 11.5 | 29.3 | 24.6 | 25.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108B USD | 8.2 | 28 | 22.6 | 25.1 | ||
AU |
CSL Ltd
ASX:CSL
|
135.3B AUD | 6.3 | 36.4 | 22 | 27.3 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.1B USD | 2.9 | 165.5 | 8.4 | 11.1 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
54.6B USD | 10.6 | -9.1 | -10.2 | -9.1 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.8B USD | 3.4 | 28.1 | 14.3 | 17.9 | ||
IE |
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 7.3 | 60.8 | 27.9 | 47 |